

AMENDMENTS TO THE SPECIFICATION:

Please replace the paragraph beginning at page 1, line 25, with the following rewritten paragraph:

--The preferred LHRH-antagonist can be CETRORELIX, TEVERELIX, ANTIDE, ABARELIX. --

Please add the following new paragraph after the paragraph ending on line 25 of page 1:

-- CETRORELIX, TEVERELIX, ANTIDE, and ABARELIX are all decapeptides with the sequences:

CETRORELEX	AC-D-Nal(2)-D-pCl-Phe-D-Pal(3)-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH ₂
TEVERELIX	AC-D-Nal(2)-D-pCl-Phe-D-Pal(3)-Ser-Tyr-D-Hcl-Lys(iPr)-Pro-D-Ala-NH ₂
ANTIDE	AC-D-Nal(2)-D-pCl-Phe-D-Pal(3)-Ser-Lys(Nic)-D-Lys(Nic)-Leu-Lys(iPr)-Pro-D-Ala-NH ₂
ABRELIX	AC-D-Nal(2)-D-pCl-Phe-D-Pal(3)-Ser-N-Me-Tyr-D-Asn-Leu-Lys(iPr)-Pro-D-Ala-NH ₂ --

Please replace the paragraph beginning at line 5 of page 2, with the following rewritten paragraph:

-- It has been found a preferred embodiment of the therapy with the LHRH-antagonist CETRORELIX.--

Please replace the paragraph beginning at line 6 of page 2, with the following rewritten paragraph:

- - CETRORELIX PAMOATE in a total dose from 30 mg to 120 mg divided in a period of 1 to 4 weeks and according to needs with repeat of the therapy every 3 to 4 months,
- CETRORELIX ACETATE in a total dose from 5 mg to 80 mg divided in a period of 1 to 8 weeks and according to needs with repeat of the therapy every 3 to 4 months.--